#Non-adrenergic Drugs

Key non-adrenergic cardiovascular drugs include **vasopressin** (and its analogues, **teripressin** and **ornipressin**), **phosphodiesterase III inhibitors** such as milrinone, and **calcium sensitisers** such as levosimendan.

| Property | Vasopressin (ADH)                                                                                                                                                      | Milrinone                                                                        | Levosimendan                                                                                                                                                                    | 
|------------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| 
            |     **Class**                 | Natural nonapeptide                                                                                                                                               | Phosphodiesterase III inhibitor                                                  | Calcium sensitiser and phosphodiesterase inhibitor                                                                                                                              | 
              |     **Uses**                | Haemorrhage, DI, catecholamine-sparing vasopressor                                                                                                                | Refractory CCF and low CO states                                                 | Severe acute heart failure                                                                                                                                                      | 
            |    **Dosing**                 | 5-10 units IV bolus, up to 4U/hr infusion                                                                                                                         |                                                                                  | Load 12-24mcg/kg over 10min, then infusion at 0.05-2mcg/kg/min                                                                                                                  | 
| **Route**               | IV/SC/IM                                                                                                                                                          | IV                                                                               |IV                                                                                                                                                                                 | 
                  | **Presentation**        | Clear solution                                                                                                                                                    | Yellow solution at 1mg/ml                                                        | 2.5mg/mL in 5ml & 10ml vials                                                                                                                                                                                | 
|**Distribution**||70% protein bound|Very high protein binding >90%|
| **Metabolism**          | t<sub>1/2</sub> 10 minutes. Metabolised by tissue peptidases and renal elimination.                                                                                | t<sub>1/2</sub> 1-2.5 hours                                                      | t<sub>1/2</sub> 1 hour. Hepatic to inactive metabolites                                                                                                                         | 
                  | **Elimination**         |                                                                                                                                                                   | 80% of drug is excreted unchanged                                                |                                                                                                                                                                                 | 
| **Mechanism of action** | V<sub>2</sub> receptors in the kidney are adenylae cyclase mediated. V<sub>1</sub> and V<sub>3</sub> receptors are phospholipase C/inositol triphosphate mediated | Inhibits phosphodiesterase breakdown of cAMP, increasing intracellular levels    | Binds to troponin C increasing myofilament Ca<sup>2+</sup> sensitivity. Also opens K<sup>+</sup> channels causing vasodilation. It may also have some PD III inhibition effect. | 
                  | **CVS**                 | ↑ SVR through vasoconstriction                                                                                                                                    | Increased inotropy, decreased SVR and PVR (PVR decreases more than SVR). Increased dysrythmias. | Increased CO without increased O<sub>2</sub> demand, vasodilation, prolonged QTc with risk of arrhythmia                                                                                                | 
                  | **GIT**                 | GIT smooth muscle contraction                                                                                                                                     |                                                                                  |                                                                                                                                                                                 | 
|                   **Renal**               | ↑ Qquaporin insertion into the collecting ducts which ↑ water reabsorption                                                                                        |                                                                                  |                                                                                                                                                                                 | 
|                   **Haematological**      | ↑coagulation factor mobilisation and ↑ platelet aggregation                                                                                                       |                                                                                  |                                                                                                                                                                                 | 
|                   **Metabolic**           | Hyponatraemia                                                                                                                                                     |                                                                                  |                                                                                                                                                                                 | 
